National comprehensive cancer network recommendations on molecular profiling of advanced bladder cancer

Sumanta Kumar Pal; Neeraj Agarwal; Stephen Anthony Boorjian; Noah M. Hahn; Arlene O. Siefker-Radtke; Peter E. Clark; Elizabeth R. Plimack

doi:10.1200/JCO.2016.68.1429

National comprehensive cancer network recommendations on molecular profiling of advanced bladder cancer

Sumanta Kumar Pal, Neeraj Agarwal, Stephen Anthony Boorjian, Noah M. Hahn, Arlene O. Siefker-Radtke, Peter E. Clark, Elizabeth R. Plimack

Urology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	3346-3348
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	34
Issue number	27
DOIs	https://doi.org/10.1200/JCO.2016.68.1429
State	Published - Sep 20 2016

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2016.68.1429

Cite this

@article{f157a807b6214ffb957a72adf13a27b2,

title = "National comprehensive cancer network recommendations on molecular profiling of advanced bladder cancer",

author = "Pal, {Sumanta Kumar} and Neeraj Agarwal and Boorjian, {Stephen Anthony} and Hahn, {Noah M.} and Siefker-Radtke, {Arlene O.} and Clark, {Peter E.} and Plimack, {Elizabeth R.}",

note = "Funding Information: Research Funding: Medivation Research Funding: Novartis (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Sanofi (Inst), Merck (Inst), Mirati Therapeutics (Inst), Oncogenex (Inst), Heat Biologics (Inst) Research Funding: National Institutes of Health, Genentech, Michael and Sherry Sutton Fund for Urothelial Cancer, Millennium Pharmaceuticals, Janssen Oncology Research Funding: Merck (Inst), Bristol-Myers Squibb (Inst), GlaxoSmithKline (Inst), Acceleron Pharma (Inst), Dendreon (Inst), Eli Lilly (Inst), AstraZeneca (Inst), Pfizer (Inst), Acerta Pharma (Inst)",

year = "2016",

month = sep,

day = "20",

doi = "10.1200/JCO.2016.68.1429",

language = "English (US)",

volume = "34",

pages = "3346--3348",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "27",

}

TY - JOUR

T1 - National comprehensive cancer network recommendations on molecular profiling of advanced bladder cancer

AU - Pal, Sumanta Kumar

AU - Agarwal, Neeraj

AU - Boorjian, Stephen Anthony

AU - Hahn, Noah M.

AU - Siefker-Radtke, Arlene O.

AU - Clark, Peter E.

AU - Plimack, Elizabeth R.

N1 - Funding Information: Research Funding: Medivation Research Funding: Novartis (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Sanofi (Inst), Merck (Inst), Mirati Therapeutics (Inst), Oncogenex (Inst), Heat Biologics (Inst) Research Funding: National Institutes of Health, Genentech, Michael and Sherry Sutton Fund for Urothelial Cancer, Millennium Pharmaceuticals, Janssen Oncology Research Funding: Merck (Inst), Bristol-Myers Squibb (Inst), GlaxoSmithKline (Inst), Acceleron Pharma (Inst), Dendreon (Inst), Eli Lilly (Inst), AstraZeneca (Inst), Pfizer (Inst), Acerta Pharma (Inst)

PY - 2016/9/20

Y1 - 2016/9/20

UR - http://www.scopus.com/inward/record.url?scp=84989903531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989903531&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.68.1429

DO - 10.1200/JCO.2016.68.1429

M3 - Article

AN - SCOPUS:84989903531

SN - 0732-183X

VL - 34

SP - 3346

EP - 3348

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 27

ER -

National comprehensive cancer network recommendations on molecular profiling of advanced bladder cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this